Fig 2.
Outcomes in 29 patients in first or later remission who received latent membrane protein (LMP) –cytotoxic T lymphocyte (CTL) as adjuvant therapy. (A) Remissions were sustained in all but one patient. (B) Two-year event-free survival for 29 patients treated with either LMP2- (n = 9) or LMP1/2-specific CTLs (n = 20; P = .22). (C) Cumulative incidence of death resulting from lymphoma or nonlymphoma causes (eg, cardiac disease, secondary malignancy, infection).